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IDENTIFIKASI HALANGAN TERHADAP RAWATAN DAN 
PENCEGAHAN MALARIA YANG EFEKTIF DI KHARTOUM, SUDAN 
 
ABSTRAK 
Malaria merupakan salah satu dari penyebab kematian yang utama di Sudan. 
Prevalens yang tertinggi adalah dalam kalangan wanita mengandung dan kanak kanak. 
Kematian dianggarkan sekitar 3500 kes setiap tahun. Hampir 13 peratus kemasukkan 
ke hospital adalah akibat dari malaria. Walaupun terdapat kemajuan Program 
Pengawalan Malaria diperingkat Nasional di Sudan, sasaran mengenai pembasmian 
dan penghapusannya tidak tercapai. Kajian semasa dijalankan untuk mengenal pasti 
halangan untuk pencegahan dan rawatan berkesan malaria di Sudan. Kajian ini 
dijalankan di negeri Khartoum. Satu kajian keratan rentas telah dijalankan untuk 
menilai amalan ahli farmasi komuniti dalam pencegahan dan rawatan malaria. Orang 
ramai di Khartoum juga dinilai untuk pengetahuan malaria mereka selain daripada 
amalan pencegahan dan rawatan mereka. Rawatan malaria di hospital awam juga 
dinilai secara retrospektif dan prospektif. Keputusan menunjukkan bahawa ahli 
farmasi komuniti tidak mempunyai pengetahuan malaria dan amalan rawatan malaria 
yang mencukupi. Lebih kurang 66.2% dari ahli farmasi komuniti yang di selidiki 
mempunyai skor pengetahuan kurang dari 50%.  Terdapat hubungan yang signifikan 
antara skor pengetahuan ahli farmasi dan menjalani latihan untuk pencegahan dan 
rawatan malaria (P-value 0.008). Kajian itu mendedahkan laporan kesan advers 
(ADRs) ubat-ubatan antimalarial yang rendah oleh ahli farmasi komuniti. Ahli farmasi 
komuniti melaporkan kekurangan pengetahuan, kekurangan latihan dan masa sebagai 
penghalang utama dalam pencegahan dan rawatan malaria serta aktiviti pelaporan 
kesan advers. Orang ramai di Khartoum menunjukkan pengetahuan yang baik 
xiv 
mengenai gejala malaria, komplikasi dan ubat-ubatan. Lebih kurang 86.9% daripada 
mereka menyatakan gigitan nyamuk merupakan penyebab utama berlakunya malaria. 
Demam dan sakit kepala merupakan simptom malaria yang kerap dilaporkan iaitu 
84.2% and 74.4% masing masing dalam kalangan orang ramai yang di kaji. Walaupun 
mereka mempunyai pengetahuan yang baik mengenai kaedah pencegahan, namun 
masih kurang digunakan dalam kalangan masyarakat. Lebih dari suku (28.9%) dalam 
kalangan mereka tidak menggunakan kaedah pencegahan malaria.Amalan diagnosis 
dan rawatan kendiri telah dilaporkan dalam kalangan orang ramai. Penilaian rawatan 
malaria di hospital awam menunjukkan ketidakpatuhan dalam banyak aspek. 
Diagnosis klinikal dan rawatan secara andaian masih berlaku dalam amalan walaupun 
terdapat kemudahan penyiasatan makmal. Dos ubat dan tempoh rawatan yang kurang 
sesuai juga dilaporkan. Laporan mengenai masalah ubat-ubatan antimalarial yang 
rendahjuga turut di dapati dalam amalan. Secara umumnya amalan rawatan malaria 
yang tidak sesuai dalam kalangan farmasi komuniti, masyarakat dan hospital awam, 
tingkah laku penggunaan ubat ubatan yang tidak sesuai dan tidak menggunakan 
kaeadah pencegahan yang sesuai oleh komuniti boleh menjadi halangan dalam cara 










IDENTIFICATION OF BARRIERS TO EFFECTIVE TREATMENT 
AND PREVENTION OF MALARIA IN KHARTOUM, SUDAN 
 
ABSTRACT 
Malaria is one of the main causes of death in Sudan. The highest prevalence is 
among children and pregnant women. The estimated deaths were 3500 cases per year. 
Near thirteen percent of the hospital admissions were due to malaria. Despite the 
achievements of the National Malaria Control Programme in Sudan, still the targets on 
eradication and elimination were not reached. The current research was carried to 
identify the barriers to effective prevention and treatment of malaria in Sudan. The 
research was conducted in Khartoum state. A prospective cross-sectional survey was 
carried to assess the community pharmacist’s practices of malaria prevention and 
treatment. The public in Khartoum were also assessed for their malaria knowledge in 
addition to their prevention and treatment practices. Malaria treatment in a public 
hospital was also investigated retrospectively and prospectively. The results showed 
that community pharmacists had inadequate malaria knowledge and malaria treatment 
practices. About 66.2% of the surveyed community pharmacists had less than 50% 
knowledge score. There was significant relationship between pharmacist knowledge 
score and receiving training on malaria prevention and treatment (P-value 0.008). The 
research revealed under reporting of antimalarial adverse drug reactions (ADRs) by 
the community pharmacists. The community pharmacists reported lack of knowledge, 
lack of training and time as main barriers to their effective contribution in malaria 
prevention and treatment and ADRs reporting activities. The publics in Khartoum 
showed good knowledge regarding malaria symptoms, complications and drugs. 
About 86.9% mentioned mosquitos’ bites as the main cause of malaria. Fever and 
xvi 
headache as malaria symptoms were reported by 84.2% and 74.4% of the surveyed 
publics.   Although they had good knowledge about prevention methods, but still under 
used by the community. More than one quarter (28.9%) were not using malaria 
prevention methods. The practices of self-diagnosis and self- treatment were reported 
among the publics. Assessment of malaria treatment in a public hospital setting 
revealed inappropriateness in many aspects. Clinical diagnosis and presumptive 
treatment were still in the practice despite availability of laboratory investigation 
facilities. In appropriate drugs dosing and duration of treatment were also reported. 
Under reporting of antimalarial drugs related problems was also in the practice. 
Generally inappropriate malaria treatment practices in community pharmacies and 
public hospital, inappropriate drug use behavior among the community and under use 
of prevention methods by the community were identified as obstacles in the way to 






Malaria is a parasitic life threatening disease .The main malaria vector is the 
infected female of Anopheles mosquitos. Malaria caused mainly by the parasite 
Plasmodium. The most identified plasmodium species are Plasmodium Falciparum, 
Plasmodium Vivax, Plasmodium Malariae, Plasmodium Oval and Plasmodium 
Knowlesi. Plasmodium Falciparum is the dominant specie in Africa and it is 
responsible of the most global malaria mortalities. Plasmodium Vivax is found in many 
countries outside Sub-Saharan Africa. Ninety percent of malaria cases and 92% of 
malaria deaths were from Sub-Saharan African countries. Seventy percent of malaria 
deaths were among children under five years of age (World Health Organization, 
2017). 
In the last few years, there was an obvious increase in efforts and funding to 
control the disease, especially by the Global Fund to Fight AIDS, Tuberculosis and 
Malaria and World Health Organization (WHO). In WHO malaria report 2016 the fund 
of malaria control and elimination was increased by US$ 0.06 billion since 2010. Many 
countries like United States of America, United Kingdom, Germany, Japan and 
Canada are contributing to this fund. The governments of the endemic countries 
contribute by about 32% of funding. This contribution will be a burden on endemic 
countries economics since the majority are developing countries (World Health 
Organization, 2017). 
The great achievements in controlling malaria appeared in many aspects. The 
number of malaria-endemic countries reduced to 90 countries compared to 108 in 2000 
without any re-establishment of malaria in any of the malaria-free countries since 
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2000. In 2015 10 countries had less than 150 indigenous cases and 9 countries had 
between 150-100 cases. Elimination of malaria from another 10 countries by 2020 is 
of the objectives of the Global Technical Strategy for Malaria 2016-2030 (World 
Health Organization, 2017). 
Increased coverage of malaria interventions between 2010 -2015 was reported. 
About 57% of the Sub-Saharan African populations benefited from indoor residual 
spraying (IRS) and insecticides treated nets (ITNs) as vector control methods. Use of 
intermittent preventive therapy (IPT) for malaria prevention during pregnancy was 
increased by 31%. 
Worldwide the malaria case incidence rates decreased by 40% between 2000-
2015 (21% between 2010 -2015). The mortality rates also decreased by 62% between 
2000-2015 (29% between 2010-2015). The decrease in mortality has led to an increase 
in the life expectancy at birth by 1.2 years in the WHO African region (World Health 
Organization, 2017). 
The WHO report also showed an increase in the access to more than fifty percent 
of the suspected cases in the African region to diagnostic testing and treatment at public 
health facilities. However, the constraints of under-resourced health systems and poor 
accessibility of most of the populations at risk to services are still there. The progress 
in malaria control is threatened by insecticides resistance and antimalarial drugs 
resistance (World Health Organization, 2017). 
 
1.2 Malaria in Sudan 
Sudan is an African country with 39 million population in 2016 (World Health 
Organization, 2016). It is classified by WHO in the Eastern Mediterranean region. 
According to World Bank income classification, it is lower to middle-income country. 
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Malaria is a real health problem in Sudan. The real burden of malaria in Sudan was 
underestimated as most of the reported data came only from the public hospitals and 
public health centers (Abdalla, Malik, & Ali, 2007). 
 People of low socioeconomic status and those who live in rural areas were the 
most affected. Still there are many problems associated with malaria diagnosis and 
treatment in Sudan. According to the last malaria indicator survey in Sudan majority 
of the people seek malaria treatment at public facilities. In public facilities malaria 
treatment was supposed to be provided free of charge, however; it was not the case 
people have to pay for the treatment. Inappropriate diagnosis and treatment were in the 
practice. Use of Monotherapy in form of Artemether injection was very high in public 
facilities. The highest use of monotherapy was reported in Khartoum state. Malaria in 
pregnancy and anemia as malaria complication were also of malaria-related problems. 
Anemia mostly affects pregnant women and children less than five years of age. 
Regarding malaria prevention still, the ownership of ITNs was low (1.4-1.8 net per 
household). Availability and use of other preventive methods were also less than the 
required. The public information on malaria was mainly obtained from the media and 
the sources of information vary from one state to another (Federal Ministry of Health, 
2017a). 
 
1.2.1 Epidemiology of malaria in Sudan 
Malaria remains one of the main causes of deaths in Sudan with a higher 
incidence among children, refugees and internally displaced people. Malaria indicator 
survey 2016 showed that malaria prevalence was 5.9% with higher prevalence among 
Children, males and pregnant females. About 12.2% of hospital admissions are due to 
malaria (Federal Ministry of Health, 2017a). 
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In 2015 the major Plasmodium species found in Sudan were P. falciparum and 
P. vivax which accounted for 95% and 5% respectively. According to malaria indicator 
survey 2016, the Plasmodium falciparum was 87.6% and the Plasmodium vivax was 
increased to 8.1%, while the mixed infection was 4.3%. P.vivax infection alone or 
mixed infection was more prevalent in Darfur, Khartoum and River Nile states. The 
prevalence of malaria in urban and rural areas differs among different states (Federal 
Ministry of Health, 2017a). 
The major Anopheles species (the vector) in Sudan are Anopheles arabiensis, 
Anopheles funestus, Anopheles gambiae, Anopheles nili, and Anopheles pharoensis. In 
the last updated WHO report 2015, the reported confirmed malaria cases in Sudan were 
586,827 while the estimated cases were 1,4 million cases. The reported deaths were 
868 while the estimated were 3500 (World Health Organization, 2017). 
Almost all the population in Sudan is at risk of malaria. The pattern of malaria 
transmission is seasonal and unstable. The transmission is dependent on rainfall while 
in urban areas, it is around the year (Federal Ministry of Health, 2017a; World Health 
Organization, 2017). 
As in different countries the epidemiology of malaria in Sudan affected by 
climatic conditions such as rainfall, humidity, temperature and floods. In Sudan a wide 
range of climate variations is available. In North state, the temperature is the main 
factor affecting the epidemiology of malaria while rainfall mainly affects Savannah 
and South state parts. Based on the climate effect researchers found that three-quarters 
of the population are at risk of endemic malaria (Aal & Elshayeb, 2011; Musa, 
Shohaimi, Hashim, & Isthrinayagy, 2012). 
In many parts of Sudan, there are irrigated agricultural projects such as 
AlGezeira area in central Sudan and AlGadarif in the east of Sudan. These projects 
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may affect the epidemiology of the disease in terms of suitable sites for mosquitoes 
breeding and some studies suggested a correlation between the use of agricultural 
pesticides and development of mosquitoes insecticides resistance (Abuelmaali et al., 
2013). 
Despite that malaria is a serious problem in Sudan some researchers reported 
underestimation of malaria burden in Sudan (Abdalla et al., 2007). Referring to the 
above-mentioned facts, even the epidemiology and the Plasmodium species are 
changing in Sudan. Increasing the efforts to achieve the goals of malaria elimination 
in Sudan is greatly required. 
 
1.2.2 Malaria prevention in Sudan 
Policies and strategies for malaria prevention recommend the use of insecticides 
treated nets (ITNs) and long-lasting insecticides treated nets (LLITNs) for all age 
groups and should be distributed free of charge but unfortunately, this is not in reality. 
Larval control and indoor residual spraying (IRS) are also of the prevention methods 
adopted by the WHO but insecticides resistance was started to rise as a problem that 
may affect the process. Resistance to some insecticides in many parts of Sudan was 
investigated and reported (K. A. Ahmed et al., 2015; Himeidan, Jones, & Ranson, 
2011). Underuse of preventive measures in many parts of Sudan could greatly affect 
the process of malaria control (H. S. Mustafa et al., 2009). As appeared in the last 
WHO updated malaria report from Sudan intermittent preventive therapy (IPT) for 
prevention of malaria in pregnancy is not routinely used. 
The availability, affordability and use of different prevention methods in terms 
of the public’s behavior and stakeholder’s implementation to different methods were 
investigated. The researchers claimed that financing and delivery of different malaria 
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prevention methods in Sudan should be critically reviewed as inappropriateness was 
noticed in many aspects (O. E. Onwujekwe et al., 2011). 
1.2.3 Malaria treatment in Sudan 
For many years Chloroquine remained as a cheap and effective first-line drug for 
malaria treatment in Sudan. Unfortunately, resistance to Chloroquine started to appear 
since 1978 but definite confirmation was in 1982. In 1988 a group of researchers 
reported in vivo and in vitro Chloroquine resistance (Abdel Hameed, 2003; Bayoumi 
et al., 1989). Since late 1990s many studies for confirmation of Chloroquine resistance 
were carried at in vivo and in vitro levels (Adam et al., 2004; Stivanello et al., 2004; 
van den Broek et al., 2003). 
In 2004 Artemisinin-based combination therapy was introduced for malaria 
treatment. Artesunate -Sulphadoxine/Pyrimethamine (AS+SP) combination was 
selected as a first-line treatment and Artemether-Lumefantrine (AL) as a second line. 
The National Malaria Control Program (NMCP), WHO, General Directorate of 
Pharmacy (GDP) and Non-Governmental Organizations (NGOs) worked together for 
implementation of the new drugs guidelines as well as withdrawal of the Chloroquine 
from the country. The new policy was faced by many obstacles such as the cost of 
treatment and the availability of drugs (E. M. Malik et al., 2006). 
Following implementation of the new policy, the researchers started to test the 
value of the new drugs in malaria treatment. The efficacy of AS+SP and AL for 
treatment of uncomplicated malaria in central Sudan was confirmed in a trial including 
137 patients. Another study confirmed the efficacy of AS+SP in treatment of 
uncomplicated malaria (E. M. Malik et al., 2006; Sakina et al., 2005). The efficacy of 
Artesunate suppositories in treatment of severe malaria was investigated and 
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documented but it was not used in the routine treatment (M. I. Awad, Alkadru, 
Behrens, Baraka, & Eltayeb, 2003).  
In malaria treatment guidelines distributed by the NMCP in 2015 uncomplicated 
malaria treated by AS+SP as a first line, AL as a second line and quinine as a third 
line. Quinine and Artemether injection were indicated for treatment of severe malaria. 
For  Malaria treatment in pregnancy, Quinine is indicated for treatment of 
uncomplicated and severe malaria in the first trimester while in the second and third 
trimesters uncomplicated malaria treated with either Quinine or AS+SP and severe 
malaria treated with Quinine and Artemether (Federal Ministry of Health, 2015). In 
2017 the NMCP launched new treatment guidelines for treatment of malaria in Sudan 
as researches reported decreased response to AS+SP (Adeel et al., 2016). 
 Artemether-Lumefantrine (AL) is recommended as a first-line treatment of 
uncomplicated malaria while Dihydroartemisinin-Piperaquine (DHAP) as a second-
line treatment. For uncomplicated cases due to P.vivax infection AL is used and 
followed by Primaquine for eradication. Treatment of severe malaria is by IV Quinine 
or IV Artesunate. In pregnancy, Quinine is indicated for treatment of uncomplicated 
and severe malaria in the first trimester while in the second and third trimesters 
uncomplicated malaria treated with either Quinine or AL or DHAP (Federal Ministry 
of Health, 2017b). 
 
1.3 Sudan Health System Profile 
Sudan is 18 states which further subdivided to 184 localities. The health system 
in Sudan is decentralized. The Federal Ministry of Health (FMOH) with 18 states 
Ministries of Health (SMOH) are responsible for ensuring the Sudanese health. The 
FMOH responsibilities are setting national policies, overall evaluation of health 
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system, international relations, cadres training and controlling epidemics of national 
threats. SMOH responsibilities are administration and financing of the health system 
and hospitals management. The localities in each state manage the family health 
centers and units. Water and sanitation services are managed by local councils. Some 
of the health facilities are under the management of private sector, Ministry of Higher 
Education, Ministry of Interior, Ministry of Defense and National Health Insurance 
Fund. The total number of public health facilities is 6,183 (765 are not functioning). 
There are 408 general hospitals, 2020 family health centers and 3.755 health units 
including dispensaries. The private hospitals are 159 in addition to 18 police and 12 
military hospitals. Full essential services are provided in less than one-quarter of the 
primary healthcare facilities. About 14% of the population has no access to the health 
facilities and this situation varies among different states.  
The Health Information System is paper-based and the reported data vary in 
completeness and quality. The reporting rate varies among facilities and the data from 
police, military and private sector hospitals is not included in the Health Information 
System. Specific information systems are found in some programs such as HIV/AIDs, 
Tuberculosis, Malaria and Expanded Programme on Immunization, however, there is 
poor coordination between the programs. 
Emergency and disasters management is the responsibility of the Emergency and 
Humanitarian Aid department which collaborate and coordinate with different 
governmental and non-governmental partners. Regarding malaria, this department is 
putting great effort in early preparedness, responding to and reducing the risk factors 
especially during the rainy season and conflicts emergencies (Federal Ministry of 
Health, 2014). 
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Health insurance in Sudan is provided through many providers. National Health 
Insurance Fund which is compulsory for formal sector employees. Khartoum State 
Health Insurance which covers only Khartoum state residents. The former two 
insurances provide services at the level of their public health facilities. Military and 
Police insurances provide services to the Ministry of Interior and Ministry of Defense 
employees and their families and they provide services at their own hospitals. Private 
Health Insurance Companies are also there, and they provide insurance for Private 
companies, International Organizations and the publics who are willing to have such 
type of insurance and they provide services through contracts with private hospitals. 
Despite the presence of different insurance providers still, a high percentage of the 
population is not covered by any type of insurance which makes their access to health 
services more difficult (A. M. A. Salim & Hamed, 2018). 
The last pharmaceutical country profile in Sudan was published in 2010. It may 
not reflect the real current situation, but it could give an idea about the pharmaceutical 
services in Sudan. The licensed pharmacists were 1.53/ 10,000 population of them 
0.39/10,000 population in the public sector. Pharmaceutical technicians and assistants 
were 0.64/10,000 population in all sectors. The licensed pharmacies were 0.59/10,000. 
In Sudan, there are 19 licensed pharmaceutical manufacturers. Their activities are 
mainly production of formulations from starting pharmaceutical materials as well as 
repackaging of different dosage forms. The research and development for the 
discovery of new active substances and starting materials in the manufacturing 
practices were not established yet. Drugs supplied mainly by the Central Medical 
Supplies Public Corporation and some private pharmaceutical importing companies. 
The Central Medical Supplies Public Corporation is mainly responsible for drug 
supply of the public sector. Registration of pharmacists, pharmacy premises, 
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pharmaceutical companies and pharmaceutical products in addition to the inspection 
of all activities related to the pharmacy profession and practices are regulated by the 
Medicines and Poisons Act,(2009), and the Medical Council Act (2004)(Federal 
Ministry of Health, 2010). 
 
1.4 Sudan National Malaria Control Programme 
Sudan Malaria Control Programme is the oldest in the tropics. Malaria control 
efforts started in Sudan in 1904 by Dr. A. Balfour who was tried to eradicate malaria 
in Khartoum through environmental control and using retained oil. After that many 
projects were carried such as Blue Nile Project and another program supported by 
Egypt to eradicate malaria in the north of Sudan. The efforts continued until launching 
of the Roll Back Malaria Initiative (RBM). The Sudan RBM strategic plan developed 
in 2002 and of its main objectives at that time was to reduce malaria morbidity and 
mortality to 50% by 2010 (Malik¹ & Khalafalla, 2004). 
A lot of interventions and activities regarding malaria control took place in Sudan 
with great support from WHO, UNICEF, UNDP, Global Fund for Fighting AIDS, 
Tuberculosis and Malaria and many other partners. A review for the Malaria 
Programme was published by the Federal Ministry of Health and the Malaria Control 
Programme showed a perceived reduction in malaria burden between 2001 and 2012. 
In 2012 the reduction in case incidence was 36% compared to 2009 and 70% compared 
to 2000. The reported deaths decreased by 46% compared to 2009. Despite the 
achievements in many aspects such as case detection and management and vector 
control it is still difficult to conclude the exact magnitude of achievements because of 
incompleteness and accuracy of the data provided by the Health Management 
Information System (Federal Ministry of Health, 2013). 
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1.5 Malaria control 
The process of malaria control is not an easy process and could be affected by 
many factors. The reports showed malaria cases and deaths were decreased worldwide 
however, malaria control is threatened by the emergence of resistance to ACTs started 
in South East Asia and insecticides resistance in Africa.(Greenwood, 2017). Despite 
the efforts to control malaria and availability of strategies and tools for that, it is still a 
major health problem especially in Africa. Estimation and tracking of malaria burden, 
strategies for transmission measurement, understanding of immunity and better 
knowledge about the mechanisms and effects of drugs and insecticides resistance 
where important challenges in malaria control as reported by researchers (Alonso & 
Tanner, 2013). Global malaria community such as governmental and non-
governmental organizations, researchers, academicians, innovators, industry and 
funders have to accelerate the development of new insecticides and other vector control 
methods as mosquitoes control is a crucial step in malaria control (Hemingway et al., 
2016). 
Besides the vector control and effective case management, the behavior of the 
targeted human population is an important factor in malaria control process. In addition 
to that, the achievement of the disease elimination is greatly influenced by sustained 
political and financial commitments in the affected countries (Newby et al., 2016). 
 
1.5.1 Effect of health services in malaria control 
The responsibility of a country health system is to deliver interventions for better 
health outcomes for the country populations. However, in low-income countries, the 
limited human resources and infrastructure may constitute obstacles in delivering 
interventions (Atun, Lazarus, Van Damme, & Coker, 2010). 
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Sustainability of achievements in malaria control depends on the performance of 
the health systems and availability of resources. Effective malaria case management is 
greatly dependent on appropriate diagnosis (microscopic or rapid diagnostic tests 
(RDTs)) and use of treatments in accordance with the guidelines. Inefficiency of health 
systems in malaria services delivery was identified in many endemic countries. It was 
reported as limited access to healthcare facilities,  inappropriate diagnosis, 
nonadherence of the care providers to treatment guidelines, ACTs stock outs and 
availability of low quality or even counterfeit and non-recommended antimalarials 
(Galactionova, Tediosi, De Savigny, Smith, & Tanner, 2015).     
Malaria treatment should be based on appropriate diagnosis. In 2009 a study 
carried in central Sudan to access the diagnosis of malaria after the introduction of 
Artemisinin combination therapy and the study revealed that more than three-quarter 
of the reviewed tests were false positive which lead to overdiagnosis and 
overestimation of the real malaria incidence (A-Elgayoum, El-Feki, Mahgoub, El-
Rayah, & Giha, 2009). 
Another study carried in eastern Sudan to detect peripheral and placental malaria 
using microscopic and RDT and it showed inaccuracy of the RDT in that setting 
(Kashif et al., 2013). The above-mentioned studies revealed inappropriate malaria 
diagnosis. Reassurance of the quality of testing is greatly needed for better estimation 
of the real burden of the disease.  
Appropriate treatment is an influential factor in malaria control. The availability, 
implementation and monitoring of valid treatment guidelines is an essential step in the 
cure of the disease.  Implementation of the guidelines could only be possible by 
training of the health worker for efficient practice as well as the availability of quality 
assured and affordable drugs.  
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Five years following the introduction of ACTs to malaria treatment in Sudan, a 
survey was done in 15 states of the country to evaluate the practice in malaria case 
management. The study showed suboptimal availability of the first and second line 
ACTs recommended by NMCP. There was unrecommended use of monotherapy in 
form of Artemether injection in 25% of the surveyed cases. The study also reported 
poor training of health workers as well as inappropriate dispensing and counseling 
practices for the patients (Abdelgader et al., 2012). 
Forty health centers located in Gezira state in central Sudan were surveyed after 
8 years of ACTs use. Irrational use of antimalarial drugs with 9.5% use of monotherapy 
(Artemether injection) was also reported. The reported irrational use of antimalarials 
could lead to the development of drugs resistance in Sudan (Elmannan et al., 2015). 
Malaria case management survey was carried out in 15 Sudanese states. About 
244 public health facilities,294 health workers and 1,643 patients were included in the 
survey. About 88.9% of the health facilities were owned by the government. Fifty-one 
percent of the facilities did not have electricity while water supply was in two third of 
the facilities. Half of the facilities had malaria treatment charts and tables and could 
provide a diagnosis of malaria through microscopical examination. RDTs were found 
in 16% of the facilities and some facilities could perform both methods of malaria 
testing. Less than half of the patients were tested for malaria. Use of non-recommended 
monotherapy (Artemether injection), presumptive treatment in 17% of the patients and 
inadequate dispensing and counseling practices were also reported. Antimalarials 
recommended by NMCP were stocked in majority of the surveyed facilities; however; 
suboptimal availability of first and second line treatments was reported. Expired drugs 
were stocked in seven facilities. Chloroquine was stocked in 5% of the facilities despite 
that it was withdrawn from malaria treatment regimens five years before the survey. 
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The main providers of health care were medical assistants of whom 52.7% received 
training by NMCP on ACTs use and only 23.5% on RDTs use. The study showed 
suboptimal malaria diagnosis and treatment practices (Abdelgader et al., 2012). 
Another study for assessment of malaria case management in children under five 
years was conducted in one of the teaching hospitals in Khartoum. The study showed 
that less than fifty percent of febrile children (43.7%) were tested for malaria and only 
22% of them had a positive malaria test. The microscopical examination was the main 
method of malaria testing, however, RDTs were done for some patients. Five of the 
children who had a positive malaria test did not receive antimalarial. Eight of children 
with negative tests and ten of those who were not tested for malaria were treated 
presumptively for malaria. Two third of the children treated for malaria, intravenous 
Quinine was given despite that signs of severe malaria were not present at admission. 
The rest of patients treated by either AS+SP or AL. Generally, the study revealed poor 
adherence to malaria treatment guidelines (Bilal et al., 2015). 
The above studies showed that the pattern of health system related constraints in 
malaria control in Sudan was not different from those reported in many endemic 
African countries. 
Despite that implementation and monitoring of malaria treatment guidelines 
should be audited by the NMCP, there is no a lot of published studies in Sudan that 
investigated the real practices of malaria treatment and antimalarial drugs used in 
hospitals as well as identification of the antimalarials drugs related problems that could 
affect the treatment outcomes. 
Sudan is a very big country in which the accessibility to health services could 
vary in different places. For example, the pastoral tribes usually move with their 
animals from place to another during dry and rainy seasons which make their reach to 
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health facilities very difficult and sometimes could be impossible. In many parts of 
Sudan community pharmacies are accessible to a great portion of the community. As 
in many African countries, publics do seek malaria treatment in community 
pharmacies, this could raise many questions such as are they provided with the 
appropriate treatment? Do the community pharmacists have the knowledge and 
training that qualified them for providing malaria treatment? Does malaria treatment 
by community pharmacists affect the process of malaria control negatively or 
positively?  
A recently published research in Sudan showed that the community pharmacists 
do dispense antimalarials without prescriptions. However, the researchers did not 
investigate the community pharmacists knowledge and training regarding malaria 
prevention and treatment practices (Elgizoli & Salim, 2017).   
 
1.5.2 Effect of community behavior in malaria control  
Despite that community participation played significant roles in some diseases 
control in many countries, its role in malaria control is not fully realized (Atkinson, 
Vallely, Fitzgerald, Whittaker, & Tanner, 2011). 
 The community contribution in the process of malaria control is an important 
component that could not be ignored. Their use of prevention methods and treatment 
seeking behavior are important factors in malaria control. Delivering interventions for 
malaria prevention and control in a community-based manner were proofed to be an 
effective method for reducing malaria burden. (Salam, Das, Lassi, & Bhutta, 2014).  
The practice of malaria self-medications among Sudanese community was 
reported by few researchers (A. Awad, Eltayeb, Matowe, & Thalib, 2005) (A.I. Awad 
& Eltayeb, 2007). Underuse of Insecticides treated nets was also reported in some parts 
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of Sudan (Hassan, Malik, Okoued, & Eltayeb, 2008) (O. B. Osman, Hamad, M.,, 
Ahmmed, & Ahmed, 2015). However, the publics knowledge about the disease and 
antimalarial drug use behavior regarding compliance to treatment, their handling of 
drugs related problems and their knowledge and use of malaria prevention methods 
were not largely investigated.  
 Now Sudan is one of the countries that controlling malaria (Newby et al., 2016). 
Malaria control is an integrated process that requires the contribution of the 
stakeholders, health workers and the community. If not, all come together roll back 
malaria will not come to reality. It took short time to change the treatment guidelines 
in Sudan from Artesunate+ Sulphadoxine / Pyrimethamine as a first line treatment in 
2015 to Artemether-Lumefantrine in 2017 compared to Chloroquine which remained 
for decades as the first-line drug for malaria treatment (Federal Ministry of Health, 
2015, 2017b). That could be due to irrational use of drugs or many other factors, 
therefore, identification of the obstacles in the way of malaria control is the first step 
for malaria elimination in Sudan. 
 
1.6 Barriers to malaria control 
Despite the efforts to control malaria, still the disease mortality and morbidities 
were higher especially in sub-Saharan African countries. The researchers tried to 
identify the barriers of malaria prevention and treatment. They related some barriers 
to communities’ knowledge. Poor knowledge about the disease causes and symptoms 
was still reported in many countries. Prevention related barriers were reported in terms 
of affordability and use of preventive methods in addition to the peoples believe that 
malaria is non preventable disease. Treatment related barriers were accessibility to 
health facilities and the quality of care provided. Compliance to treatment and 
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treatment cost were other obstacles of malaria control.  Treatment related wrong 
believes such as that convulsions due to severe disease is spiritual and should be treated 
by traditional healers. Some communities have concern about the effectiveness of 
treatment at hospitals and efficacy and use of medications (Maslove et al., 2009). 
Another group of researchers tried to identify the barriers at the level of policy 
making. They reviewed the literatures and interviewed policy makers and stakeholders 
in three East African countries (Kenya, Uganda and Tanzania). They mentioned some 
barriers that were related to individual’s characteristics and behaviors such as disease 
knowledge, adherence to malaria control regimens and cultural believes. Poverty and 
limited resources could not be ignored. Health system related barriers were mainly 
related to accessibility to health care facilities, availability of drugs and other malaria 
control measures. Health systems capacities, organization, infrastructures and research 
priorities were also of the identified barriers. Financial resources constitute a major 
determinant of the decision-making process in malaria control. The cost of malaria 
control materials and drugs regimens determination and implementation is high as it 
requires training at all levels from approval to diagnosis and prescribing. The policy 
process of malaria control is fragmented process that require collaboration of different 
ministries such as Health, Environment and many other partners (Paul et al., 2015). 
Different patterns of malaria transmissions may exist at one country or one 
region. That could be an obstacle in the way of malaria control.  It was suggested that 
malaria control programs should design different malaria control policies that suits the 
ecological, environmental and social needs of each area. Additional prevention 
methods such as malaria seasonal chemoprevention, genetic modification of 
mosquitoes, mosquito traps as well as transmission blocking drugs and vaccines should 
be implemented (Greenwood, 2017).       
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1.7 Rationale of the Study 
By the broad cause of death malaria, HIV and tuberculosis are the top killing 
disease in Sudan as reported by WHO. The process of malaria control is a complex 
process and could be achievable only by appropriate prevention and treatment which 
need collaboration between community and healthcare professionals. In Sudan 
community pharmacists are contributing in the process of malaria prevention and 
treatment as the situation in many Asian and African countries but there was no a lot 
of published research in Sudan that elaborated this role. Elgizoli & Salim, (2017) 
published a research showed that community pharmacists in Khartoum were 
dispensing antimalarials without prescriptions, however; they did not evaluate the 
knowledge of pharmacists regarding malaria and its prevention and treatment. This 
will be the first study to assess the knowledge, and practice of the community 
pharmacists in malaria prevention, treatment and reporting of antimalarial drugs 
ADRs. Now in Sudan, we are in a transitional stage to the concept of pharmacist 
patient-oriented practice and still many people are looking for the pharmacist as drug 
dispenser rather than care provider. The community perception to the role of the 
pharmacist in malaria treatment will be investigated. The community knowledge about 
malaria prevention and antimalarials use behavior is an important component of 
malaria control because unless the community awareness about the disease and its 
prevention and treatment is good enough the control will not be accomplished. This 
may raise many questions regarding malaria control such as: 
1-Is malaria appropriately treated in public hospitals? 
2-Do the community pharmacists have the knowledge about malaria prevention 
and treatment? 
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3-Do the community pharmacists practice regarding antimalarials dispensing 
affecting the malaria control process negatively or positively? 
4-Do the public have the knowledge about malaria prevention and treatment? 
5-Is the antimalarials use behavior among the public affect the malaria control 
process negatively or positively? 
The findings of the study could show the situation of malaria prevention and 

















1.8 Study Objectives 
1.8.1 General objective 
Identification of barriers to effective prevention and treatment of malaria in 
Khartoum, Sudan. 
1.8.2 Specific objectives 
1- Assessment of the effect and contribution of pharmaceutical services in malaria 
prevention and treatment by assessing of the community pharmacist knowledge 
and practice in prevention and treatment of malaria. 
2- Assessment of the perception of the community pharmacists to their role in 
malaria prevention and treatment and their role in reporting ADRs of 
antimalarials. 
3- Assessment of the public’s knowledge, and practice regarding malaria 
prevention and treatment. 
4- Assessment of the public’s perception to the role of community pharmacist in 
malaria prevention and treatment  
5-  Evaluation of malaria treatment in a public hospital setting with special 









2.1 Malaria economic burden 
2.1.1 Global burden 
Funding for malaria control and elimination is increasing annually with up to 
one-third of this fund provided by endemic countries governments. Contribution of 
international fund in malaria elimination and control could be provided as a direct aid 
to endemic countries or through Global Fund, World Bank or other institution. Part of 
the fund directed to malaria research in many fields such as antimalarial medicines 
which took the majority of research funding as well the research in malaria vaccines 
and basic research (World Health Organization, 2017). 
The relation between malaria and poverty was studied in different countries. 
Researchers related malaria and poverty in many aspects. Increased incidence of 
malaria was reported among poor people lives in houses built from deciduous materials 
and of poor hygiene. Residing far from health services and inability to pay for the 
prevention and treatment services were also of the factors led to increased incidence, 
morbidity and mortality  of the disease among poor communities  (Bi & Tong, 2014; 
Obaldia, 2015; Sonko et al., 2014; Yadav, Dhiman, Rabha, Saikia, & Veer, 2014). 
African countries suffer high economic burden of malaria. Studies were carried 
in many countries to estimate this problem. Hospital and households’ surveys were 
carried in Nigeria to estimate the cost of treatment and the economic burden of the 
disease. Majority of the surveyed populations were farmers. The results showed that 
the cost of treatment was a real problem not only for the poor community but also to 
the health system (Ibitoye, Shaibu, Sanda, & Ajayi, 2016; O. Onwujekwe et al., 2013). 
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In Malawi, the cost of malaria treatment was assessed for inpatients. The high 
cost of treatment exceeds the average daily income of majority of the Malawians. The 
days lost from work for the patients and their caregivers and the days lost from school 
were also considered as a part of the economic burden of the disease. The high cost of 
treatment may affect the treatment-seeking behavior of the patients and the control of 
malaria in such poor communities (Hennessee et al., 2017). 
The economic burden of malaria in six African countries (Chad, Mali, Nigeria, 
Rwanda, Ghana, and Uganda) was assessed between 2002 and 2005. The researchers 
reported that malaria had a significant negative effect on the economic growth of the 
studied countries. They recommended that increasing investment in malaria control 
could help in the development of poor communities in African countries  (Okorosobo, 
Okorosobo, Mwabu, Orem, & Kirigia, 2011). 
 Private sectors investment in malaria control in collaboration with international 
agencies and local governments of endemic countries will improve the economic 
development of these countries as it will increase the efficiency of employees as well 
as directing the spending to development and education.(Purdy, Robinson, Wei, & 
Rublin, 2013).The relationship between increasing income and malaria reduction in 
100 countries was studied and a positive relation was reported (Datta & Reimer, 2013).  
 
2.1.2 Malaria burden in Sudan 
Sudan is classified as middle to low-income country; therefore, the cost of 
malaria treatment could be a real burden and it will have an obvious impact in 
economic. The cost of treatment is usually assessed as a direct cost which includes 
medical consultation, investigations, hospitalization and drugs. Indirect cost could be 
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expressed in terms of morbidities, mortalities and days lost from work or school for 
both patients and caregivers (M. H. Mustafa & Babiker, 2007). 
Gezira state is one of the most important agricultural areas in Sudan because 
most of the crops with high economic return (such as cotton) are grown there. The 
effect of malaria on farmers’ productivity was investigated. The researchers reported 
a loss of farmers’ efficiency and working hours which greatly affected their economic 
status because agriculture was their main source of income. The reduction in farmers 
productivity could have a negative impact on the country economy (Nur, 1993). 
Malaria care expenditure was estimated in Wad-Medani central Sudan (it is the 
capital of Gezira state). The cost of treatment was calculated for hospitalized patients 
(adults and children) and outpatients. It was found that the cost of treatment in 
hospitalized patients was more than the patients who treated at home. Treatment in 
private settings was more costly than public settings. The bulk of the cost of treatment 
was the cost of medications. The researchers concluded that the cost of malaria 
treatment was a burden for all socioeconomic classes (Abdel-Hameed, Abdalla, & 
Alnaury, 2001). 
The cost of malaria treatment in public health centers and private pharmacies 
was assessed in six Sudanese states (Khartoum, River Nile, Red Sea, Northern 
Kordofan, Southern Darfur and Gadarif). The research revealed that the patients spent 
an average cost of about 2 days of their lowest government salary for their malaria 
treatment. There was a slight increase in the cost of treatment in private pharmacies 
compared to public health centers (Cheraghali & Idries, 2009). 
In 2004 a household survey was carried in Khartoum state to estimate the 
economic burden of malaria. The direct and indirect cost of treatment was found to be 
a real burden especially in households who were not working in government or even 
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private formal sectors because they were not covered by health insurance and majority 
of them were paid on daily basis. The research revealed that the medication cost was 
the higher followed by consultation fees. Treatment cost was higher in private clinics 
compared to public health centers and hospitals (M. H. Mustafa & Babiker, 2007). 
The economic burden of malaria in three areas of Khartoum was also studied. 
Families of different socioeconomic status were assessed for their income, 
environment in their homes and surroundings, their treatment seeking behavior and 
use of preventive measures. High prevalence of the disease and inappropriate treatment 
seeking was reported in families with low income (Mahgoub, 2017). 
A study carried in Sinnar state, Sudan showed that the cost of treatment was a 
real obstacle in malaria control. Researchers suggested that reduction of the treatment 
fees could be of great value in improving the treatment-seeking behavior of the 
community (Abdu, Mohammed, Bashier, & Eriksson, 2004). 
 
2.2 Community perception of malaria and its treatment 
Control of diseases in different communities could be affected by the social and 
cultural behaviors and practices of the community. Researches showed a lot of 
differences in the communities’ knowledge, attitudes and practices in malaria 
prevention and treatment. 
In Ghana, a survey was carried in two villages. The people there have their own 
names to malaria, they called it “Pua”. They failed to describe the adequate relation 
between malaria, mosquitos and stagnant water. Part of the surveyed people could 
mention some malaria symptoms. The respondents mentioned that bed nets could be 
used for prevention of nuisance rather than malaria. They believe that anemia and 
convulsions were spiritual diseases that mainly treated by traditional healers. Some 
